FDA supplemental approval: Pomalidomide (REMS)

AI Summary

This record documents FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for pomalidomide oral capsules (1 mg, 2 mg, 3 mg, and 4 mg) manufactured by Hetero Labs Ltd, approved on 27 April 2026. The record is an administrative action and contains no clinical trial results, efficacy data, or safety outcomes; it does not support any clinical evidence claim.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for pomalidomide generic formulations; this is a regulatory action, not clinical evidence of efficacy or safety.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This approval permits distribution of pomalidomide generic formulations under a REMS programme; it does not establish efficacy, safety, or comparative benefit. Clinicians should refer to the approved REMS protocol and existing pomalidomide labelling for clinical guidance.

Caveats

• This is a regulatory action record and does not contain clinical trial results, efficacy data, safety outcomes, or comparative analysis.
• The record does not describe the specific content or requirements of the approved REMS program.
• No information is provided regarding the clinical development or bioequivalence of the generic formulations.
• This approval does not constitute evidence of clinical practice guidance or superiority over other treatments.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.